Wall Street Zen Downgrades IQVIA (NYSE:IQV) to Hold

IQVIA (NYSE:IQV) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

A number of other equities analysts also recently issued reports on the stock. Cowen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 9th. Barclays boosted their price target on IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Thursday, October 2nd. BMO Capital Markets started coverage on IQVIA in a research note on Thursday, November 13th. They issued an “outperform” rating and a $260.00 price objective on the stock. Finally, UBS Group boosted their price objective on IQVIA from $225.00 to $250.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $241.44.

IQVIA Stock Performance

Shares of NYSE IQV opened at $225.68 on Friday. The firm’s 50-day moving average price is $214.48 and its 200-day moving average price is $187.05. IQVIA has a 52-week low of $134.65 and a 52-week high of $234.29. The company has a market cap of $38.43 billion, a PE ratio of 30.96, a PEG ratio of 2.53 and a beta of 1.37. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The company had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the prior year, the firm earned $2.84 earnings per share. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts anticipate that IQVIA will post 10.84 EPS for the current year.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On IQVIA

Institutional investors have recently bought and sold shares of the stock. Physician Wealth Advisors Inc. lifted its stake in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after buying an additional 131 shares in the last quarter. Westside Investment Management Inc. boosted its stake in IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC purchased a new position in IQVIA during the 3rd quarter valued at approximately $30,000. Finally, Atlantic Union Bankshares Corp bought a new stake in IQVIA in the 3rd quarter worth approximately $36,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.